Prometic Life Scie Com Npv (PFSCF) Lowered to “Hold” at Zacks Investment Research
Prometic Life Scie Com Npv (NASDAQ:PFSCF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.
According to Zacks, “ProMetic Life Sciences Inc. is a biopharmaceutical company. The company is involved in bioseparations, plasma-derived therapeutics and small-molecule drug development. Its operating segment consists of Therapeutics and Protein Technology. Therapeutics segment products include PBI-4050 for treatment of fibrosis with chronic kidney diseases, certain cancers and side effects associated with chemotherapy; PBI-4419, an anti-fibrotic and anti-inflammatory compound for kidney injury and chronic kidney diseases and PBI-1402 for the treatment of anemia indications. Protein Technology segment provides plasma protein purification system, bioseparation products and prion capture/pathogen removal technology platform. ProMetic Life Sciences Inc. is headquartered in Laval, Canada. “
Shares of Prometic Life Scie Com Npv (NASDAQ:PFSCF) opened at 2.186 on Wednesday. The company’s 50 day moving average price is $2.23 and its 200-day moving average price is $2.33. Prometic Life Scie Com Npv has a 52 week low of $1.29 and a 52 week high of $2.77. The stock’s market capitalization is $1.32 billion.
Receive News & Stock Ratings for Prometic Life Scie Com Npv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prometic Life Scie Com Npv and related stocks with our FREE daily email newsletter.